Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved revenue of 13.7533 million yuan during the reporting period, an increase of 52,604.25% over the previous year. The net loss attributable to shareholders of listed companies was 400 million yuan, and the net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 432 million yuan. The loss increased year-on-year.
亚虹医药(688176.SH)发布2023年度业绩 核心产品均处于在研状态 净亏损扩大至4亿元
Yahong Pharmaceutical (688176.SH) announced 2023 annual results, all core products are under development, and net loss increased to 400 million yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.